Retrospective Analysis for Patients With Metabolic Syndrome
Retrospective Analysis of Outpatient Intervention Effects in Patients With Metabolic Syndrome
Asset
Semaglutide
GLP-1 agonist
Listed sites
1
Recruiting sites
1
Estimated enrollment
400
Study population
Metabolic syndrome, Obesity / overweight
Eligibility highlights
-
Primary endpoint
•Weight
Registered trial locations
Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Who this study enrolls
Who can enroll
Study population text
This was a retrospective study of the weight loss effect in 1 to 3 months in overweight or obese individuals at the department of clinical nutrition in the Second Affiliated Hospital of Zhejiang University, School of Medicine in China between 1 January 2020 and 1 Janu-ary 2024.
Inclusion criteria
• individuals who had at least a 2 follow up visits with a BMI of 24 or more with the pri-mary goal of losing weight.
Exclusion criteria
Endpoints (3)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Weight & body composition
3 endpointsweight
Time frame:0month/1month/2months/3 months
descriptive, improvement
visceral fat area(VFA)
Time frame:0month/1month/2months/3 months
Visceral fat, change
change from baseline, improvement
skeletal muscle mass(SMM)
Time frame:0month/1month/2months/3 months
Lean mass
change from baseline, improvement
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.